Eli Lilly has established itself as the market leader in obesity drugs in Europe, Asia and the Middle East and expects to ...

Novo Nordisk , looking to turn around slowing growth of its blockbuster weight-loss drug Wegovy, plans to test whether its ...

That means shifting cooking methods, moderating portions, and tackling obesogenic environments like 24-hour eateries and ...

Childhood obesity rates have surpassed those of undernutrition for the first time, suggesting efforts to combat malnutrition ...

Eli Lilly & Co.’s obesity pill prompted enough weight loss in a large clinical trial to be meaningful for patients and have ...

Details of a new drug that aims to treat the underlying causes of obesity are being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria ...

The over-representation of males and Hispanic patients in Eli Lilly’s Phase III ATTAIN-1 study could explain why orforglipron ...

An investigational small-molecule, nonpeptide oral GLP-1 receptor agonist significantly reduced weight in adults with obesity ...

What if your smart watch could sense when you're about to raid the fridge, and gently steer you toward a healthier choice ...

Eli Lilly's orforglipron outperformed Novo Nordisk’s semaglutide for type 2 diabetes, showing greater weight loss and blood ...

An oral GLP-1 induced significantly greater weight loss than placebo for adults with obesity or overweight plus one ...

The 'Be the Reason Kids Greaux Healthy' conference is taking place on October 2-3 to address Louisiana's childhood obesity ...